Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mercuri

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Nature Medicine|June 26, 2026
Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trialPeter C Kahr, Fabian Aus dem Siepen, Olivier Lairez, et al.
The New England Journal of Medicine|December 13, 2017
Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismGary E Raskob, Nick van Es, Peter Verhamme, et al.
Thrombosis Research|March 11, 2020
Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]F I Mulder, N van Es, N Kraaijpoel, et al.
Thrombosis Research|November 17, 2019
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer studyF I Mulder, N van Es, N Kraaijpoel, et al.
Thrombosis and Haemostasis|July 31, 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer StudyNoémie Kraaijpoel, Marcello Di Nisio, Frits I Mulder, et al.
Thrombosis and Haemostasis|August 15, 2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer studyNick van Es, Marcello Di Nisio, Suzanne M Bleker, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Nature Medicine|June 26, 2026
Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trialPeter C Kahr, Fabian Aus dem Siepen, Olivier Lairez, et al.
The New England Journal of Medicine|December 13, 2017
Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismGary E Raskob, Nick van Es, Peter Verhamme, et al.
Thrombosis Research|March 11, 2020
Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]F I Mulder, N van Es, N Kraaijpoel, et al.
Thrombosis Research|November 17, 2019
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer studyF I Mulder, N van Es, N Kraaijpoel, et al.
Thrombosis and Haemostasis|July 31, 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer StudyNoémie Kraaijpoel, Marcello Di Nisio, Frits I Mulder, et al.
Thrombosis and Haemostasis|August 15, 2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer studyNick van Es, Marcello Di Nisio, Suzanne M Bleker, et al.
Pageof 10